News from durect corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 27, 2015, 16:15 ET

DURECT to Participate in Upcoming Healthcare Conferences

DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.  -...

Aug 03, 2015, 16:05 ET

DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs

 DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2015.  Total revenues were $4.4 million and...

Jul 24, 2015, 16:30 ET

DURECT Corporation Invites You to Join its Second Quarter 2015 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2015 financial results press release, you are invited to listen to the...

Jun 29, 2015, 16:30 ET

DURECT to Present at the Cantor Fitzgerald Healthcare Conference

DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Healthcare...

Jun 23, 2015, 08:00 ET

DURECT Announces Plans for a New POSIDUR™ (SABER®-Bupivacaine) Clinical Trial

 DURECT Corporation (Nasdaq: DRRX) announced that, based on feedback from the FDA, it plans to conduct a new POSIDUR™...

May 18, 2015, 08:30 ET

DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study

DURECT Corporation (Nasdaq: DRRX) today announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral...

Apr 30, 2015, 19:36 ET

DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs

 DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2015.  Total revenues were $4.8 million and...

Apr 22, 2015, 16:30 ET

DURECT Corporation Invites You to Join its First Quarter 2015 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the...

Mar 30, 2015, 08:30 ET

DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study

DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the...

Mar 02, 2015, 16:03 ET

DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs

 DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2014. Total revenues were $4.3...

Mar 02, 2015, 16:02 ET

DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development

 DURECT Corporation (Nasdaq: DRRX) today announced its Epigenomic Regulator Program, and the successful completion of a Phase 1 clinical trial...

Feb 23, 2015, 16:15 ET

DURECT Corporation Invites You to Join its Fourth Quarter 2014 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the...

Jan 29, 2015, 16:15 ET

DURECT to Present at the BIO CEO & Investor Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor...

Dec 16, 2014, 08:00 ET

DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product

 DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen...

Dec 01, 2014, 16:30 ET

DURECT to Present at the Oppenheimer Healthcare Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Oppenheimer 25th Annual...

Nov 11, 2014, 16:05 ET

DURECT Provides Update on POSIDUR™ Program

 DURECT Corporation (Nasdaq: DRRX) announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23,...

Nov 03, 2014, 16:05 ET

DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014.  Total revenues were $4.3 million and net...

Oct 27, 2014, 08:05 ET

DURECT Provides Update on REMOXY® and POSIDUR™ Programs

 DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc....

Oct 24, 2014, 16:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time.

DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the...

Oct 10, 2014, 08:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the American Society of Anesthesiologists Annual Meeting

DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for...